The first single-dose flu drug nod could be FDA’s Christmas present for Roche

When Shionogi got Japanese approval for its novel flu drug Xofluza (baloxavir marboxil) in February, it didn’t expect a U.S. decision in 2018. Now, an FDA priority review has made it possible for its partner Roche to get a go-ahead before New Year's.